Acurx Pharmaceuticals Inc

ACXP

Company Profile

  • Business description

    Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

  • Contact

    259 Liberty Avenue
    Staten IslandNY10305
    USA

    T: +1 917 533-1469

    https://www.acurxpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    4

Stocks News & Analysis

stocks

ASX gold miner under pressure to sell by activist investor

Activist investor presses gold miner on selling to larger players.
stocks

Ask the Analyst: Will Amcor lose its dividend aristocrat status?

When consistency becomes constraint.
stocks

Chart of the Week: We see opportunity in this beaten down industrial player

The market sees risks and are discounting the shares excessively.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,916.9058.60-0.65%
CAC 408,244.2993.871.15%
DAX 4024,944.95149.010.60%
Dow JONES (US)51,516.90829.831.64%
FTSE 10010,360.3228.020.27%
HKSE25,253.40379.81-1.48%
NASDAQ26,878.7224.750.09%
Nikkei 22567,470.69931.45-1.36%
NZX 50 Index13,101.6113.47-0.10%
S&P 5007,588.1534.470.46%
S&P/ASX 2008,686.1059.50-0.68%
SSE Composite Index4,057.7826.19-0.64%

Market Movers